What is ABCL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.90B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ABCL?

P/E (TTM) is n/a and 52-week range is $2.75 to $15.02 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ABCL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ABCL?

The company profile lists revenue (TTM) near $70M, net income (TTM) near -$17.46B, EPS (TTM) near -$0.54 when available from the market-data feed. Figures are informational and may lag live markets.

Where is AbCellera Biologics Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Vancouver, British Columbia, CA, 323.9M shares outstanding, ISIN CA00288U1066 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

AbCellera Biologics Inc.

$ABCL

Health Care · Life Sciences Tools & Services

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 562 full-time employees. The company went IPO on 2020-12-11. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Employees

562

Website

www.abcellera.com/

IPO

2020-12-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

CA00288U1066

Headquarters

Vancouver, British Columbia, CA

Shares outstanding

323.9M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

36.70%

Browse other companiesFree AI scores and summaries for more stocks